Halozyme Appoints Barbara Duncan to its Board of Directors

About this update from Halozyme Therapeutics, Inc.

[{"type":"text","content":"SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry.\n\"We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board,\" said Dr. Helen Torley, president and chief executive officer. \"Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company.\"\nMs. Duncan most recently served as the Chief Financial Officer of Intercept Pharmaceuticals Inc., a biopharmaceutical company, from 2009 to 2016. Prior to Intercept, Ms. Duncan held senior leadership roles at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and Chief Executive Officer. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance -Global Healthcare at Lehman Brothers Inc.\n\"It's an exciting opportunity to join Halozyme as a board member at this juncture of their success,\" said Barbara Duncan. \"With their disruptive drug delivery technologies and patient centric mission, I look forward to supporting Halozyme's continued growth and success.\"\nMs. Duncan holds a Master of Business Administration from the Wharton School, University of Pennsylvania and a Bachelor of Business Administration in Accounting from Louisiana State University.\nAbout Halozyme\nHalozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx,...

More updates from Halozyme Therapeutics, Inc.